4Filing Date: Mar 10, 2026

Dexcom (DXCM)

Statement of Changes in Beneficial Ownership

View SEC Filing
ACC: 0001093557-26-000047
Total Value$1.17M
Trades2
Insiders1

Transaction Details

Stern Sadie
EVP, Chief HR Officer·Direct
Grant · Acquire
Common Stock
Shares+39.02K
Price$0.00
Total Value$0
Shares Owned After148.71K
Transaction DateMar 8, 2026
Footnotes ▸

Represents a grant of restricted stock units (RSUs) that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. RSUs represent a contingent right to receive one share of DexCom, Inc. Common Stock.

Stern Sadie
EVP, Chief HR Officer·Direct
Tax W/H · Dispose
Common Stock
Shares-17.20K
Price$68.10
Total Value$1.17M
Shares Owned After131.51K
Transaction DateMar 8, 2026
Footnotes ▸

Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of RSUs and does not represent a sale by the Reporting Person. | Included in this number are 77,603 unvested RSUs, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 11,399 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027.

Post-Transaction Holdings

Stern Sadie · EVP, Chief HR Officer
SecuritySharesChange
Common Stock148.71K+21.82K (17.20%)
Original SEC Filing Textexpand_more
=== SEC Form 4 — Statement of Changes in Beneficial Ownership === Document Type: 4 Period of Report: 2026-03-08 10b5-1 Pre-arranged Plan: No --- Issuer --- Name: DEXCOM INC (DXCM) CIK: 0001093557 --- Reporting Owner --- Name: Stern Sadie CIK: 0001797971 Role: Officer (EVP, Chief HR Officer) --- Non-Derivative Transactions --- [Transaction #1] Security: Common Stock Date: 2026-03-08 | Code: A (Grant or award) Shares: +39,019 | Price: $0.00 Shares Owned After: 148,709 | Ownership: D (Direct) Footnotes: [F1] Represents a grant of restricted stock units (RSUs) that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. RSUs represent a contingent right to receive one share of DexCom, Inc. Common Stock. [Transaction #2] Security: Common Stock Date: 2026-03-08 | Code: F (Payment of exercise/tax) Shares: -17,199 | Price: $68.10 Total Value: $1,171,251.90 Shares Owned After: 131,510 | Ownership: D (Direct) Footnotes: [F2] Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of RSUs and does not represent a sale by the Reporting Person. [F3] Included in this number are 77,603 unvested RSUs, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 11,399 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027. --- Footnotes (Complete Index) --- F1: Represents a grant of restricted stock units (RSUs) that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. RSUs represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2: Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of RSUs and does not represent a sale by the Reporting Person. F3: Included in this number are 77,603 unvested RSUs, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 11,399 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027. --- Signature --- /s/ /s/ Jereme M. Sylvain, as Attorney-in-Fact for Sadie Stern (2026-03-10)

keid analysis is for reference only and does not constitute investment advice.